PT2305715T - Anticorpo monoclonal para a proteína de ligação a osteoprotegerina - Google Patents

Anticorpo monoclonal para a proteína de ligação a osteoprotegerina

Info

Publication number: PT2305715T
Authority: PT; Portugal
Prior art keywords: binding protein; monoclonal antibody; osteoprotegerin binding; opgbp; antibodies
Prior art date: 2000-02-23

Application number

PT100130418T

Other languages

English (en)

Inventor

V Deshpande Rajendra

Hitz Anna

J Boyle William

K Sullivan John

Original Assignee

Amgen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-02-23

Filing date

2001-02-23

Publication date

2017-03-02

2001-02-23 Application filed by Amgen Inc filed Critical Amgen Inc

2017-03-02 Publication of PT2305715T publication Critical patent/PT2305715T/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Orthopedic Medicine & Surgery (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Mycology (AREA)
Obesity (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

PT100130418T 2000-02-23 2001-02-23 Anticorpo monoclonal para a proteína de ligação a osteoprotegerina PT2305715T (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US51113900A	2000-02-23	2000-02-23
US09/791,153 US20030103978A1 (en)	2000-02-23	2001-02-22	Selective binding agents of osteoprotegerin binding protein

Publications (1)

Publication Number	Publication Date
PT2305715T true PT2305715T (pt)	2017-03-02

Family

ID=24033610

Family Applications (5)

Application Number	Title	Priority Date	Filing Date
PT01911158T PT1257648E (pt)	2000-02-23	2001-02-23	Agentes antagonísticos de ligação selectiva da proteína de ligação da osteoprotegerina
PT100105865T PT2330197E (pt)	2000-02-23	2001-02-23	Agentes antagonísticos de ligação selectiva da proteína de ligação da osteoprotegerina
PT80109911T PT2105449T (pt)	2000-02-23	2001-02-23	Agentes antagonísticos de ligação selectiva da proteína de ligação da osteoprotegerina
PT100130418T PT2305715T (pt)	2000-02-23	2001-02-23	Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
PT161988126T PT3184545T (pt)	2000-02-23	2001-02-23	Agentes antagonísticos de ligação seletiva da proteína de ligação da osteoprotegerina

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
PT01911158T PT1257648E (pt)	2000-02-23	2001-02-23	Agentes antagonísticos de ligação selectiva da proteína de ligação da osteoprotegerina
PT100105865T PT2330197E (pt)	2000-02-23	2001-02-23	Agentes antagonísticos de ligação selectiva da proteína de ligação da osteoprotegerina
PT80109911T PT2105449T (pt)	2000-02-23	2001-02-23	Agentes antagonísticos de ligação selectiva da proteína de ligação da osteoprotegerina

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT161988126T PT3184545T (pt)	2000-02-23	2001-02-23	Agentes antagonísticos de ligação seletiva da proteína de ligação da osteoprotegerina

Country Status (13)

Country	Link
US (2)	US20030103978A1 (pt)
EP (5)	EP3613775A1 (pt)
JP (7)	JP5279425B2 (pt)
AT (1)	ATE398676T2 (pt)
CY (5)	CY1108297T1 (pt)
DK (4)	DK1257648T4 (pt)
ES (5)	ES2758881T3 (pt)
HK (1)	HK1158696A1 (pt)
LT (1)	LT2105449T (pt)
MX (2)	MX363225B (pt)
PT (5)	PT1257648E (pt)
SI (3)	SI2105449T1 (pt)
TW (1)	TWI322182B (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL117175A (en) *	1995-02-20	2005-11-20	Sankyo Co	Osteoclastogenesis inhibitory factor protein
JP2002509431A (ja) *	1996-12-23	2002-03-26	イミュネックス・コーポレーション	ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
DE122010000049I1 (de) *	1997-04-15	2011-05-05	Daiichi Sankyo Co Ltd	Neues protein und verfahren zu dessen herstellung
US6316408B1 (en) *	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
CZ302262B6 (cs) *	1997-04-16	2011-01-19	Amgen Inc.	Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající
PT2009025E (pt)	1998-05-14	2011-09-19	Immunex Corp	Método de inibição da actividade dos osteoclastos
US7718776B2 (en) *	2002-04-05	2010-05-18	Amgen Inc.	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US7052694B2 (en) *	2002-07-16	2006-05-30	Mayo Foundation For Medical Education And Research	Dendritic cell potentiation
JP4134166B2 (ja) *	2003-04-30	2008-08-13	独立行政法人科学技術振興機構	ヒト抗ヒトインターロイキン−１８抗体およびその断片、並びにそれらの利用方法
US20060099203A1 (en) *	2004-11-05	2006-05-11	Pease Larry R	B7-DC binding antibody
WO2006017759A2 (en) *	2004-08-05	2006-02-16	Kirin Brewery Co., Ltd.	Tumor endothelial marker-1 (tem1) binding antibodies and uses thereof
PE20070684A1 (es) *	2005-11-14	2007-08-06	Amgen Inc	MOLECULAS QUIMERICAS DE ANTICUERPO RANKL-PTH/PTHrP
US20080107597A1 (en) *	2006-01-12	2008-05-08	Anaptys Biosciences, Inc.	Isolation of antibodies that cross-react and neutralize rankl originating from multiple species
BRPI0906387A2 (pt)	2008-02-05	2015-07-07	Bristol Myers Squibb Co	Anticorpos alfa 5 - beta 1 e seus usos
JP2012506695A (ja) *	2008-08-20	2012-03-22	ヤンセンバイオテツク，インコーポレーテツド	改変された抗ｉｌ−１３抗体、組成物、方法、及び使用
WO2010047515A2 (ko)	2008-10-20	2010-04-29	광주과학기술원	바이포달 펩타이드 바인더
WO2011071280A2 (ko) *	2009-12-11	2011-06-16	광주과학기술원	세포내 타겟 결합용 바이포달 펩타이드 바인더
US10752664B2 (en)	2011-04-08	2020-08-25	Amgen Inc.	Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
EA201491413A1 (ru)	2012-01-26	2015-03-31	Эмджен Инк.	Полипептиды фактора роста и дифференцировки 15 (gdf-15)
UY35148A (es)	2012-11-21	2014-05-30	Amgen Inc	Immunoglobulinas heterodiméricas
US9753030B2 (en)	2013-03-06	2017-09-05	University of Pittsburgh—of the Commonwealth System of Higher Education	Degradable carbon nanotube-containing biosensors and methods for target clinical marker detection
WO2014144817A2 (en)	2013-03-15	2014-09-18	Amgen Inc.	Inhibitory polypeptides specific to wnt inhibitors
DK3027642T3 (da)	2013-07-31	2020-11-02	Amgen Inc	Vækstdifferentieringsfaktor 15 (gdf-15)-konstruktioner
EP3712166A1 (en)	2013-09-05	2020-09-23	Amgen Inc.	Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
WO2015175861A1 (en)	2014-05-16	2015-11-19	Amgen Inc.	Assay for detecting th1 and th2 cell populations
SG11201703403TA (en)	2014-10-27	2017-05-30	Agency Science Tech & Res	Anti-tim-3 antibodies
GB201419094D0 (en)	2014-10-27	2014-12-10	Agency Science Tech & Res	Anti-TIM-3-antibodies
AU2016301361B2 (en)	2015-08-05	2022-06-16	Janssen Biotech, Inc.	Anti-CD154 antibodies and methods of using them
AU2018235928B2 (en)	2017-03-14	2023-09-21	Amgen Inc.	Control of total afucosylated glycoforms of antibodies produced in cell culture
IL313983A (en)	2018-03-26	2024-08-01	Amgen Inc	Total afucosylated glycoforms of antibodies produced in cell culture
CN111954537A (zh)	2018-04-09	2020-11-17	美国安进公司	生长分化因子15融合蛋白
KR20220069982A (ko)	2019-09-26	2022-05-27	암젠 인크	항체 조성물의 생산 방법
US20230273126A1 (en)	2020-06-04	2023-08-31	Amgen Inc.	Assessment of cleaning procedures of a biotherapeutic manufacturing process
TW202221024A (zh) *	2020-08-07	2022-06-01	美商索倫多醫療公司	結合sars-cov-2 s蛋白之中和抗體
CA3197930A1 (en)	2020-10-15	2022-04-21	Amgen Inc.	Relative unpaired glycans in antibody production methods
CA3222409A1 (en)	2021-06-07	2022-12-15	Amgen Inc.	Using fucosidase to control afucosylation level of glycosylated proteins
WO2023059607A1 (en)	2021-10-05	2023-04-13	Amgen Inc.	Fc-gamma receptor ii binding and glycan content
WO2023215725A1 (en)	2022-05-02	2023-11-09	Fred Hutchinson Cancer Center	Compositions and methods for cellular immunotherapy
WO2024220916A1 (en)	2023-04-20	2024-10-24	Amgen Inc.	Methods of determining relative unpaired glycan content

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3773919A (en) *	1969-10-23	1973-11-20	Du Pont	Polylactide-drug mixtures
US4179337A (en) *	1973-07-20	1979-12-18	Davis Frank F	Non-immunogenic polypeptides
US4263428A (en)	1978-03-24	1981-04-21	The Regents Of The University Of California	Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en)	1981-02-16	1987-12-09	Ici Plc	Continuous release pharmaceutical compositions
US4474893A (en) *	1981-07-01	1984-10-02	The University of Texas System Cancer Center	Recombinant monoclonal antibodies
EP0088046B1 (de)	1982-02-17	1987-12-09	Ciba-Geigy Ag	Lipide in wässriger Phase
US4816567A (en) *	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4615885A (en)	1983-11-01	1986-10-07	Terumo Kabushiki Kaisha	Pharmaceutical composition containing urokinase
DE3572982D1 (en)	1984-03-06	1989-10-19	Takeda Chemical Industries Ltd	Chemically modified lymphokine and production thereof
US4699880A (en) *	1984-09-25	1987-10-13	Immunomedics, Inc.	Method of producing monoclonal anti-idiotype antibody
US4959314A (en) *	1984-11-09	1990-09-25	Cetus Corporation	Cysteine-depleted muteins of biologically active proteins
US6150090A (en) *	1986-01-09	2000-11-21	Massachusetts Institute Of Technology	Nuclear factors associated with transcriptional regulation
US5106627A (en) *	1987-11-17	1992-04-21	Brown University Research Foundation	Neurological therapy devices
US5158881A (en)	1987-11-17	1992-10-27	Brown University Research Foundation	Method and system for encapsulating cells in a tubular extrudate in separate cell compartments
US4892538A (en) *	1987-11-17	1990-01-09	Brown University Research Foundation	In vivo delivery of neurotransmitters by implanted, encapsulated cells
US5846534A (en) *	1988-02-12	1998-12-08	British Technology Group Limited	Antibodies to the antigen campath-1
JP3192651B2 (ja)	1988-05-27	2001-07-30	アムジェン，インコーポレーテッド	インターロイキン―１インヒビター
US5011472A (en) *	1988-09-06	1991-04-30	Brown University Research Foundation	Implantable delivery system for biological factors
DE68925966T2 (de)	1988-12-22	1996-08-29	Kirin Amgen Inc	Chemisch modifizierte granulocytenkolonie erregender faktor
JP2877509B2 (ja)	1989-05-19	1999-03-31	アムジエン・インコーポレーテツド	メタロプロテイナーゼ阻害剤
WO1992009697A1 (en) *	1990-11-30	1992-06-11	Celtrix Laboratories, Inc.	USE OF A BONE MORPHOGENETIC PROTEIN IN SYNERGISTIC COMBINATION WITH TGF-β FOR BONE REPAIR
US6565841B1 (en)	1991-03-15	2003-05-20	Amgen, Inc.	Pulmonary administration of granulocyte colony stimulating factor
US5118667A (en) *	1991-05-03	1992-06-02	Celtrix Pharmaceuticals, Inc.	Bone growth factors and inhibitors of bone resorption for promoting bone formation
MX9204303A (es) *	1991-07-23	1993-11-01	Rhone Poulenc Rorer Int	Factor regulador del crecimiento de osteoclasto.
US5961974A (en) *	1991-10-25	1999-10-05	Immunex Corporation	Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
WO1993015722A1 (en)	1992-02-07	1993-08-19	Syntex (Usa) Inc.	Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) *	1992-04-01	1993-08-10	Eastman Kodak Company	Method of making a projection viewable transparency comprising an electrostatographic toner image
US5578569A (en) *	1993-03-12	1996-11-26	Tam; Cherk S.	Method of increasing bone growth
US5457035A (en) *	1993-07-23	1995-10-10	Immunex Corporation	Cytokine which is a ligand for OX40
ATE202571T1 (de) *	1993-09-14	2001-07-15	Merck & Co Inc	Humane protein-tyrosinphosphatase decodierende cdna
US5641747A (en) *	1994-07-25	1997-06-24	Temple University-Of The Commonwealth System Of Higher Education	Treatment of osteopetrotic diseases
US7094564B1 (en) *	1995-03-15	2006-08-22	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
US20030166097A1 (en) *	1995-03-15	2003-09-04	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor
US5843901A (en)	1995-06-07	1998-12-01	Advanced Research & Technology Institute	LHRH antagonist peptides
KR101004174B1 (ko) *	1995-06-29	2010-12-24	임뮤넥스 코포레이션	세포소멸을 유도하는 시토킨
US6369027B1 (en) *	1995-12-22	2002-04-09	Amgen Inc.	Osteoprotegerin
US6613544B1 (en) *	1995-12-22	2003-09-02	Amgen Inc.	Osteoprotegerin
US6046048A (en) *	1996-01-09	2000-04-04	Genetech, Inc.	Apo-2 ligand
US5981220A (en) *	1996-03-27	1999-11-09	Human Genome Sciences, Inc.	Epidermal differentiation factor
TW555765B (en)	1996-07-09	2003-10-01	Amgen Inc	Low molecular weight soluble tumor necrosis factor type-I and type-II proteins
CN1245534A (zh) *	1996-12-13	2000-02-23	先灵公司	哺乳动物细胞表面抗原及相关试剂
WO1998028423A2 (en) *	1996-12-20	1998-07-02	Board Of Regents, The University Of Texas System	Compositions and methods of use for osteoclast inhibitory factors
JP2002509431A (ja) *	1996-12-23	2002-03-26	イミュネックス・コーポレーション	ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
US6271349B1 (en) *	1996-12-23	2001-08-07	Immunex Corporation	Receptor activator of NF-κB
DE122010000049I1 (de) *	1997-04-15	2011-05-05	Daiichi Sankyo Co Ltd	Neues protein und verfahren zu dessen herstellung
AU7142498A (en)	1997-04-15	1998-11-11	Genetics Institute Inc.	Secreted proteins and polynucleotides encoding them
US5843678A (en) *	1997-04-16	1998-12-01	Amgen Inc.	Osteoprotegerin binding proteins
US6316408B1 (en) *	1997-04-16	2001-11-13	Amgen Inc.	Methods of use for osetoprotegerin binding protein receptors
CZ302262B6 (cs) *	1997-04-16	2011-01-19	Amgen Inc.	Izolovaná nukleová kyselina, polypeptid kódovaný touto nukleovou kyselinou, expresní vektor obsahující tuto nukleovou kyselinu, hostitelská bunka transfekovaná tímto expresním vektorem, izolovaný protein vázající osteoprotegerin, protilátka vázající
WO1998054201A1 (en) *	1997-05-29	1998-12-03	Human Genome Sciences, Inc.	Human tumor necrosis factor receptor-like protein 8
US6087555A (en) *	1997-10-15	2000-07-11	Amgen Inc.	Mice lacking expression of osteoprotegerin
US7063960B2 (en) *	1997-12-12	2006-06-20	The Rockefeller University	Protein belonging to the TNF superfamily involved in signal transduction, nucleic acids encoding same, and methods of use thereof
PT2009025E (pt) *	1998-05-14	2011-09-19	Immunex Corp	Método de inibição da actividade dos osteoclastos
TR200100737T2 (tr) *	1998-09-15	2001-07-23	Pharmexa A/S	Osteoprotegerin ligand aktivitesini düzenleme yöntemi
US6884598B2 (en) *	2000-09-22	2005-04-26	Immunex Corporation	Screening assays for agonists and antagonists of receptor activator of NF-κB
DE02726901T1 (de) *	2001-05-17	2004-07-15	Immunex Corp., Seattle	Therapeutische verwendung von rang-antagonisten
CA2449658A1 (en) *	2001-06-06	2002-12-12	Immunex Corporation	Use of rank antagonists to treat cancer
RS54274B1 (en) *	2001-06-26	2016-02-29	Amgen Fremont Inc.	Opgl antibodies
US7084257B2 (en) *	2001-10-05	2006-08-01	Amgen Inc.	Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
US7718776B2 (en) *	2002-04-05	2010-05-18	Amgen Inc.	Human anti-OPGL neutralizing antibodies as selective OPGL pathway inhibitors
US9300829B2 (en)	2014-04-04	2016-03-29	Canon Kabushiki Kaisha	Image reading apparatus and correction method thereof

2001
- 2001-02-22 US US09/791,153 patent/US20030103978A1/en not_active Abandoned
- 2001-02-23 PT PT01911158T patent/PT1257648E/pt unknown
- 2001-02-23 EP EP19203092.2A patent/EP3613775A1/en not_active Ceased
- 2001-02-23 ES ES16198812T patent/ES2758881T3/es not_active Expired - Lifetime
- 2001-02-23 SI SI200131071T patent/SI2105449T1/sl unknown
- 2001-02-23 TW TW090104205A patent/TWI322182B/zh not_active IP Right Cessation
- 2001-02-23 DK DK01911158.2T patent/DK1257648T4/en active
- 2001-02-23 PT PT100105865T patent/PT2330197E/pt unknown
- 2001-02-23 ES ES10010586.5T patent/ES2505144T3/es not_active Expired - Lifetime
- 2001-02-23 EP EP16198812.6A patent/EP3184545B1/en not_active Expired - Lifetime
- 2001-02-23 EP EP10010586.5A patent/EP2330197B1/en not_active Expired - Lifetime
- 2001-02-23 SI SI200130847T patent/SI1257648T1/sl unknown
- 2001-02-23 PT PT80109911T patent/PT2105449T/pt unknown
- 2001-02-23 PT PT100130418T patent/PT2305715T/pt unknown
- 2001-02-23 EP EP08010991.1A patent/EP2105449B1/en not_active Expired - Lifetime
- 2001-02-23 DK DK10013041.8T patent/DK2305715T3/en active
- 2001-02-23 MX MX2013014759A patent/MX363225B/es unknown
- 2001-02-23 ES ES08010991T patent/ES2738798T3/es not_active Expired - Lifetime
- 2001-02-23 DK DK10010586.5T patent/DK2330197T3/en active
- 2001-02-23 SI SI200131038T patent/SI2330197T1/sl unknown
- 2001-02-23 LT LTEP08010991.1T patent/LT2105449T/lt unknown
- 2001-02-23 AT AT01911158T patent/ATE398676T2/de active
- 2001-02-23 ES ES10013041.8T patent/ES2612124T3/es not_active Expired - Lifetime
- 2001-02-23 DK DK16198812.6T patent/DK3184545T3/da active
- 2001-02-23 ES ES01911158.2T patent/ES2307594T5/es not_active Expired - Lifetime
- 2001-02-23 PT PT161988126T patent/PT3184545T/pt unknown
- 2001-02-23 EP EP10013041.8A patent/EP2305715B1/en not_active Expired - Lifetime
2002
- 2002-08-21 MX MX2019002926A patent/MX2019002926A/es unknown
2008
- 2008-08-26 CY CY20081100919T patent/CY1108297T1/el unknown
- 2008-09-17 JP JP2008237535A patent/JP5279425B2/ja not_active Expired - Lifetime
2011
- 2011-12-08 HK HK11113289.0A patent/HK1158696A1/xx not_active IP Right Cessation
2013
- 2013-01-10 JP JP2013002331A patent/JP5747048B2/ja not_active Expired - Lifetime
- 2013-03-14 US US13/830,441 patent/US20140147444A1/en not_active Abandoned
2014
- 2014-10-10 CY CY20141100821T patent/CY1115634T1/el unknown
- 2014-12-09 JP JP2014248643A patent/JP5981981B2/ja not_active Expired - Lifetime
2016
- 2016-05-31 JP JP2016109167A patent/JP6453810B2/ja not_active Expired - Lifetime
2017
- 2017-01-11 CY CY20171100035T patent/CY1118462T1/el unknown
- 2017-10-17 JP JP2017200890A patent/JP6647730B2/ja not_active Expired - Lifetime
2018
- 2018-08-24 JP JP2018156987A patent/JP2019022486A/ja active Pending
2019
- 2019-08-26 CY CY20191100907T patent/CY1121931T1/el unknown
- 2019-12-17 CY CY20191101324T patent/CY1122686T1/el unknown
- 2019-12-24 JP JP2019232697A patent/JP2020062034A/ja active Pending

Also Published As

Publication number	Publication date
CY1115634T1 (el)	2017-01-04
JP5279425B2 (ja)	2013-09-04
JP5747048B2 (ja)	2015-07-08
JP2019022486A (ja)	2019-02-14
EP3184545A1 (en)	2017-06-28
EP2305715A2 (en)	2011-04-06
EP2305715A3 (en)	2012-07-25
SI1257648T1 (sl)	2008-10-31
ES2738798T3 (es)	2020-01-27
ES2612124T3 (es)	2017-05-12
JP6453810B2 (ja)	2019-01-16
JP2015131800A (ja)	2015-07-23
HK1158696A1 (en)	2012-07-20
EP2305715B1 (en)	2016-12-07
MX2019002926A (es)	2019-07-18
PT2105449T (pt)	2019-10-18
CY1122686T1 (el)	2021-03-12
CY1118462T1 (el)	2017-07-12
TWI322182B (en)	2010-03-21
JP5981981B2 (ja)	2016-08-31
SI2105449T1 (sl)	2019-09-30
EP2105449B1 (en)	2019-07-03
ES2758881T3 (es)	2020-05-06
JP2020062034A (ja)	2020-04-23
US20030103978A1 (en)	2003-06-05
LT2105449T (lt)	2019-08-12
EP3613775A1 (en)	2020-02-26
US20140147444A1 (en)	2014-05-29
EP2330197A3 (en)	2013-05-29
CY1121931T1 (el)	2020-10-14
PT1257648E (pt)	2008-09-19
EP2105449A3 (en)	2013-03-13
JP2018064555A (ja)	2018-04-26
MX363225B (es)	2019-03-15
EP2105449A2 (en)	2009-09-30
ATE398676T2 (de)	2008-07-15
EP2330197B1 (en)	2014-09-10
DK2305715T3 (en)	2017-03-13
DK2330197T3 (en)	2014-12-15
JP2009060904A (ja)	2009-03-26
EP2330197A2 (en)	2011-06-08
PT3184545T (pt)	2020-01-06
DK1257648T3 (da)	2008-10-27
JP6647730B2 (ja)	2020-02-14
SI2330197T1 (sl)	2015-02-27
DK1257648T4 (en)	2016-11-28
EP3184545B1 (en)	2019-10-16
DK3184545T3 (da)	2020-01-06
CY1108297T1 (el)	2014-02-12
JP2013135670A (ja)	2013-07-11
ES2307594T3 (es)	2008-12-01
PT2330197E (pt)	2014-10-15
ES2307594T5 (es)	2017-01-30
JP2016196476A (ja)	2016-11-24
ES2505144T3 (es)	2014-10-09

Publication	Publication Date	Title
PT2305715T (pt)	2017-03-02	Anticorpo monoclonal para a proteína de ligação a osteoprotegerina
JOP20190017A1 (ar)	2017-06-16	أجسام مضادة ترتبط مع مستقبل cgrp بشري
WO2002020569A3 (en)	2003-01-23	Mammalian genes; related reagents and methods
WO2004046306A3 (en)	2004-10-28	Fully human antibody fab fragments with human interferon-gamma neutralizing activity
BR0011849A (pt)	2003-05-27	Anticorpos enxertados lm609 melhorados
NO20025354L (no)	2003-01-10	Pattedyr-reseptorproteiner; beslektede reagenser og fremgangsmåter
NZ591636A (en)	2012-10-26	Sclerostin binding agents
WO2006089230A3 (en)	2006-11-16	Human monoclonal antibodies to prostate specific membrane antigen (psma)
WO2001090358A3 (en)	2003-01-23	Mammalian receptor proteins; related reagents and methods
DK1392359T4 (da)	2013-06-10	Specifikke bindingsproteiner og deres anvendelser.
WO2001090151A3 (en)	2002-10-17	Human receptor proteins; related reagents and methods
WO2001036467A3 (en)	2002-05-10	Mammalian receptor proteins; related reagents and methods
WO2001057219A3 (en)	2002-03-07	Mammalian interleukin-1-delta and -epsilon. their use in therapeutic and diagnostic methods
WO2001025432A3 (en)	2001-09-07	Histamine receptor
WO2005065711A3 (en)	2005-09-01	Mammalian receptor proteins; related reagents and methods
NZ512332A (en)	2004-02-27	Potassium channel interactors and uses therefor
WO2005058362A3 (en)	2006-01-12	Method for opening tight junctions comprising the use of jam-1, claudin-4 and occludin protein antagonists as well as sirna molecules
TW202506715A (zh)	2025-02-16	抗原結合域及其使用方法
SE9902899D0 (sv)	1999-08-13	New peptides, corresponding antibodies, and compositions thereof
WO2003046125A3 (en)	2004-07-08	Hin-2 nucleic acid molecules, proteins, antibodies, homologues, receptors, and uses thereof